The complement C3-complement factor D-C3a receptor signalling axis regulates cardiac remodelling in right ventricular failure

[1]  T. Woodruff,et al.  The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist , 2021, Frontiers in Pharmacology.

[2]  E. Behr,et al.  Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway? , 2021, European heart journal.

[3]  N. Trayanova,et al.  Nanoscale Study of Calcium Handling Remodeling in Right Ventricular Cardiomyocytes Following Pulmonary Hypertension. , 2020, Hypertension.

[4]  Y. Hiraoka,et al.  HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse , 2020, Scientific Reports.

[5]  J. Thurman,et al.  Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement? , 2020, Global cardiology science & practice.

[6]  P. Nilsson,et al.  Complement component C3 and the TLR co-receptor CD14 are not involved in angiotensin II induced cardiac remodelling. , 2020, Biochemical and biophysical research communications.

[7]  J. Thurman,et al.  Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension , 2020, American journal of respiratory and critical care medicine.

[8]  P. Amouyel,et al.  Circulating proteomic signature of early death in heart failure patients with reduced ejection fraction , 2019, Scientific Reports.

[9]  P. Nilsson,et al.  Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis , 2019, The Journal of Immunology.

[10]  J. Lambris,et al.  New insights into the immune functions of complement , 2019, Nature Reviews Immunology.

[11]  M. Dalakas.  Immunotherapy in myasthenia gravis in the era of biologics , 2018, Nature Reviews Neurology.

[12]  E. Takimoto,et al.  Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload , 2018, PloS one.

[13]  M. Guazzi,et al.  Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction , 2017, European journal of heart failure.

[14]  R. Brodsky,et al.  Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.

[15]  Giuseppe Faggian,et al.  T cell costimulation blockade blunts pressure overload-induced heart failure , 2017, Nature Communications.

[16]  John D Lambris,et al.  Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense , 2016, Immunological reviews.

[17]  Dean Y. Li,et al.  Small Molecule-Induced Complement Factor D (Adipsin) Promotes Lipid Accumulation and Adipocyte Differentiation , 2016, PloS one.

[18]  John D. Lambris,et al.  Complement in disease: a defence system turning offensive , 2016, Nature Reviews Nephrology.

[19]  G. Fonarow,et al.  Epidemiology and aetiology of heart failure , 2016, Nature Reviews Cardiology.

[20]  G. Filippatos,et al.  Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology , 2016, European journal of heart failure.

[21]  S. Thiel,et al.  Complement activation, regulation, and molecular basis for complement‐related diseases , 2015, The EMBO journal.

[22]  V. Frémeaux-Bacchi,et al.  Complement System Part I – Molecular Mechanisms of Activation and Regulation , 2015, Front. Immunol..

[23]  Lubka T. Roumenina,et al.  Complement System Part II: Role in Immunity , 2015, Front. Immunol..

[24]  T. Woodruff,et al.  Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-evaluating the Evidence and the Myth , 2015, The Journal of Immunology.

[25]  R. Berger,et al.  Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? , 2015, Heart Failure Reviews.

[26]  Soichi Nagao,et al.  Anterograde C1ql1 Signaling Is Required in Order to Determine and Maintain a Single-Winner Climbing Fiber in the Mouse Cerebellum , 2015, Neuron.

[27]  G. Taglialatela,et al.  NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease , 2015, Neuron.

[28]  L. Jonasson,et al.  A vital role for complement in heart disease. , 2014, Molecular immunology.

[29]  Yulin Li,et al.  Antagonist of C5aR prevents cardiac remodeling in angiotensin II-induced hypertension. , 2014, American journal of hypertension.

[30]  Hui-Hua Li,et al.  Complement 5a Receptor Mediates Angiotensin II–Induced Cardiac Inflammation and Remodeling , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[31]  M. Mehra,et al.  Right Heart Failure: Toward a Common Language , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[33]  Bärbel Rohrer,et al.  Detection of complement activation using monoclonal antibodies against C3d. , 2013, The Journal of clinical investigation.

[34]  Wuding Zhou,et al.  C3a and C5a promote renal ischemia-reperfusion injury. , 2012, Journal of the American Society of Nephrology : JASN.

[35]  D. Bernstein,et al.  Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. , 2012, Physiological genomics.

[36]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[37]  Y. Oade,et al.  Arrhythmogenic right ventricular cardiomyopathy , 2011, BMJ Case Reports.

[38]  Jin Wu,et al.  Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation , 2010, Science.

[39]  G. Filippatos,et al.  Effects of Right Ventricular Ejection Fraction on Outcomes in Chronic Systolic Heart Failure , 2010, Circulation.

[40]  Kurt R Stenmark,et al.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[41]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[42]  M. Ratajczak,et al.  DEFECTIVE ENGRAFTMENT OF C3aR-/- HEMATOPOIETIC STEM PROGENITOR CELLS REVEALS A NOVEL ROLE OF THE C3a-C3aR AXIS IN BONE MARROW HOMING , 2009, Leukemia.

[43]  R. Smith,et al.  Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. , 2008, Blood.

[44]  T. Shioya.  A simple technique for isolating healthy heart cells from mouse models. , 2007, The journal of physiological sciences : JPS.

[45]  M. Kirby,et al.  Heart field: from mesoderm to heart tube. , 2007, Annual review of cell and developmental biology.

[46]  J. Chrast,et al.  Comparison of contraction and calcium handling between right and left ventricular myocytes from adult mouse heart: a role for repolarization waveform , 2006, The Journal of physiology.

[47]  Shinsuke Yuasa,et al.  Analysis of the electrophysiological properties and arrhythmias in directly contacted skeletal and cardiac muscle cell sheets. , 2005, Cardiovascular research.

[48]  Qing Nie,et al.  Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. , 2004, Physiological genomics.

[49]  Yibin Wang,et al.  Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. , 2004, Trends in cardiovascular medicine.

[50]  H. Okada,et al.  Inactivation of C3a and C5a Octapeptides by Carboxypeptidase R and Carboxypeptidase N , 2002, Microbiology and immunology.

[51]  J. Volanakis,et al.  Complement activation in factor D-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Frøland,et al.  Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment , 2001, Circulation.

[53]  M. Cleman,et al.  Serum complement activation in congestive heart failure. , 2001, American heart journal.

[54]  O. Götze,et al.  C3a(desArg) does not bind to and signal through the human C3a receptor. , 1999, Immunology letters.

[55]  J Ross,et al.  Molecular and physiological alterations in murine ventricular dysfunction. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Texter Ec.  Toward a common language. , 1975, Journal of the Tennessee Medical Association.

[57]  M. Vandenheuvel,et al.  right ventricular function and failure , 2014 .

[58]  P. Freedson,et al.  Scientific Statement From the American Heart Association Guide to the Assessment of Physical Activity: Clinical and Research Applications: A , 2015 .